drugset / Trial / NCT03020095
Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of Ravidasvir (ASC16) in combination with Ritonavir-boosted Danoprevir(ASC08) and Ribavirin in treatment-naive no-cirrhotic Taiwanese patients who have chronic hepatitis C genotype1.
Timeline
- Start
- 2015-08
- Primary completion
- 2016-08
- Completion
- 2017-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ravidasvir | Small molecule | 200 mg | Oral |
| Background | Ribavirin | Small molecule | 1000 mg | Oral |
| Background | Ribavirin | Small molecule | 1200 mg | Oral |
| Background | Ritonavir | Other / unclassified | 100 mg | Oral |
| Background | danoprevir | Small molecule | 100 mg | Oral |